DTC For Accelerated Approval Drugs: US FDA Is Taking Another Look At Disclosure On Websites

 
• By Brenda Sandburg
  
Generate a summary of this article
Listen to this article
Beta

Study will assess responses of cancer survivors and caregivers to disclosures that a drug received accelerated approval. FDA analysis found that 73% of 26 accelerated approval drugs cited approval pathway on product websites.

accelerated
FDA to assess consumer reaction to disclosure of drug's accelerated approval in product website • Source: Alamy

The US Food and Drug Administration plans to conduct another study to determine whether disclosure that a product received accelerated approval impacts consumer perceptions of the drug. The research project comes as accelerated approval is in the public spotlight following the FDA’s approval of Biogen, Inc. and Eisai Co., Ltd.’s ’s Alzheimer’s disease drug Aduhelm (aducanumab) via this pathway.

The proposed study by FDA’s Office of Prescription Drug Promotion is specifically evaluating the responses of cancer survivors and their...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By Saba Afreen

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>